TNFSF10 and cancer: Collectively, the above preclinical trials provide strong evidence that SMs can enhance the anticancer activity of TNFα, TRAIL, and chemotherapeutic agents, as well as radiosensitization in diverse tumor types; these findings suggest the therapeutic potential of such combinations for the treatment of human cancer.